Straits Times Index
3,331.70 +5.42 (+0.16%) S&P 500
5,467.93 -1.37 (-0.03%) Dow
39,131.43 +19.27 (+0.05%) Nasdaq
17,755.76 +38.11 (+0.22%) Bitcoin USD
60,766.16 -1,125.39 (-1.82%) CMC Crypto 200
1,262.42 -21.36 (-1.66%)
GlaxoSmithKline Pharmaceuticals Limited (GLAXO.NS)
- Benzinga
Why Is Moderna Stock Trading Lower On Wednesday?
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, and COVID-19 vaccines. In the presentation slides to the U.S. agency, Moderna Inc (NASDAQ:MRNA) shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up. The data showed that vaccine efficacy fell to around 50% after 18 months on participants aged
- The Telegraph
Britain snubs GSK in favour of US pharma giant for RSV vaccine
The NHS has turned to US drugs giant Pfizer over its British rival GSK for vaccines against Respiratory Syncytial Virus (RSV), the winter infection known as the “silent killer” of the elderly.
- The Telegraph
The $3bn crisis casting a shadow over Dame Emma Walmsley’s GSK
As Dame Emma Walmsley stood up to deliver GSK’s latest set of results last month, she was brimming with confidence. This was “another excellent” period, she said, with sales and profits at the company booming.
